- Home
- OMCL vs PVLA Comparison
OMCL vs PVLA Comparison
Compare OMCL & PVLA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | OMCL | PVLA |
|---|---|---|
| Founded | 1992 | 2015 |
| Country | United States | United States |
| Employees | N/A | 14 |
| Industry | Computer Manufacturing | Biotechnology: Pharmaceutical Preparations |
| Sector | Technology | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 1.9B | 1.6B |
| IPO Year | 2000 | N/A |
Fundamental Metrics
Financial Performance| Metric | OMCL | PVLA |
|---|---|---|
| Price | $38.08 | $108.48 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 6 | 15 |
| Target Price | $55.83 | ★ $171.87 |
| AVG Volume (30 Days) | ★ 476.6K | 211.3K |
| Earning Date | 04-28-2026 | 05-12-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ N/A |
| EPS | ★ 0.25 | N/A |
| Revenue | ★ $787,309,000.00 | N/A |
| Revenue This Year | $6.77 | N/A |
| Revenue Next Year | $5.22 | $104,350.18 |
| P/E Ratio | $151.28 | ★ N/A |
| Revenue Growth | ★ 9.93 | N/A |
| 52 Week Low | $26.85 | $20.20 |
| 52 Week High | $51.84 | $151.18 |
Technical Indicators
Market Signals| Indicator | OMCL | PVLA |
|---|---|---|
| Relative Strength Index (RSI) | 35.32 | 44.84 |
| Support Level | $35.44 | $101.29 |
| Resistance Level | $45.06 | $117.35 |
| Average True Range (ATR) | 1.75 | 6.49 |
| MACD | -0.83 | -0.42 |
| Stochastic Oscillator | 17.63 | 41.05 |
Price Performance
Historical ComparisonAbout OMCL Omnicell Inc. ($0.001 par value)
Omnicell Inc provides automation and business analytics software for healthcare providers. The company is engaged in transforming the pharmacy and nursing care delivery model. The company helps its customers define and deliver cost-effective medication management designed to equip and empower pharmacists and nurses to focus on patient care rather than administrative tasks and drive improved clinical, operational, and financial outcomes across all care settings. The company derives the majority of its revenue from the United States.
About PVLA Palvella Therapeutics Inc.
Palvella Therapeutics Inc is a late clinical-stage biopharmaceutical company committed to serving individuals suffering from serious, rare genetic skin diseases without approved therapies. The Company's lead product candidate, QTORIN 3.9 percent rapamycin anhydrous gel (QTORIN rapamycin), is based on the Company's patented QTORIN platform. QTORIN rapamycin is in clinical development for two rare genetic skin disorders.